IBI-3003
- Generic Name
- IBI-3003
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06083207
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺St Vincent's Hospital, Melbourne, Victoria, Australia
🇦🇺Wollongong Private Hospital, Wollongong, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath